ScholarIQanswers from OpenAlex
Institute for Neurodegenerative Disorders
InstitutionResearch output, impact & collaborations
Institute for Neurodegenerative Disorders is a institution indexed in ScholarIQ from OpenAlex.
What is known about Institute for Neurodegenerative Disorders?
ScholarIQrecord summary
Institute for Neurodegenerative Disorders is a research organisation in New Haven, US. OpenAlex records 4,472 works and 736,491 citations for it. 1,203 researchers list it as their most recent affiliation.
How many works does Institute for Neurodegenerative Disorders have?
ScholarIQindexed works
Institute for Neurodegenerative Disorders has 4,472 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institute for Neurodegenerative Disorders have?
ScholarIQcitation count
Institute for Neurodegenerative Disorders has 736,491 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Institute for Neurodegenerative Disorders?
ScholarIQresearcher count
Institute for Neurodegenerative Disorders has 1,203 researchers in the ScholarIQ index.
What is the average h-index at Institute for Neurodegenerative Disorders?
ScholarIQavg h-index
Institute for Neurodegenerative Disorders has an average h-index of 81 in OpenAlex.
What is the ROR of Institute for Neurodegenerative Disorders?
ScholarIQror
The ROR for Institute for Neurodegenerative Disorders is on the source record.
What is the OpenAlex record for Institute for Neurodegenerative Disorders?
ScholarIQopenalex
The OpenAlex for Institute for Neurodegenerative Disorders is on the source record.
Who are the most-cited researchers behind Institute for Neurodegenerative Disorders?
ScholarIQtop researchers by citations
What are the most-cited papers on Institute for Neurodegenerative Disorders?
ScholarIQmost cited works
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma, Daniela Berg, Matthew Stern, Werner Poewe, C. Warren Olanow, Wolfgang H. Oertel, José Á. Obeso, Kenneth Marek, Irene Litvan, Anthony E. Lang, Glenda M. Halliday, Christopher G. Goetz, Thomas Gasser, Bruno Dubois, Piu Chan, Bastiaan R. Bloem, Charles H. Adler, Günther Deuschl
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek, Danna Jennings, Shirley Lasch, Andrew Siderowf, Caroline M. Tanner, Tanya Simuni, Christopher S. Coffey, Karl Kieburtz, Emily Flagg, Sohini Chowdhury, Werner Poewe, Brit Mollenhauer, Paracelsus-Elena Klinik, Todd Sherer, Mark Frasier, Claire C. Meunier, Alice Rudolph, Cindy Casaceli, John Seibyl, Susan Mendick, Norbert Schuff, Ying Zhang, Arthur W. Toga, Karen Crawford, Alison B. Ansbach, Pasquale De Blasio, Michele Piovella, John Q. Trojanowski, Les Shaw, Andrew Singleton, Keith A. Hawkins, Jamie L. Eberling, Deborah W. Brooks, David Russell, Laura Leary, Stewart A. Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David G. Standaert, Stephanie Guthrie, Robert A. Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Hegeman Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly A. Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltán Mari, Melissa Gerstenhaber, David J. Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor D. Grachev, Kim P. Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony W. Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor
MDS research criteria for prodromal Parkinson's disease
Daniela Berg, Ronald B. Postuma, Charles H. Adler, Bastiaan R. Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G. Goetz, Glenda M. Halliday, Lawrence Joseph, Anthony E. Lang, Inga Liepelt‐Scarfone, Irene Litvan, Kenneth Marek, José Á. Obeso, Wolfgang H. Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern, Günther Deuschl
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf, Luis Concha‐Marambio, David-Erick Lafontant, Carly M. Farris, Yihua Ma, Paula A. Urenia, Hieu Nguyen, Roy N. Alcalay, Lana M. Chahine, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, John Seibyl, Tanya Simuni, Caroline M. Tanner, Daniel Weintraub, Aleksandar Videnović, Seung Ho Choi, Ryan Kurth, Chelsea Caspell‐Garcia, Christopher S. Coffey, Mark Frasier, Luís M. A. Oliveira, Samantha J. Hutten, Todd Sherer, Kenneth Marek, Claudio Soto
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S. Coffey, Chelsea Caspell‐Garcia, Tanya Simuni, Danna Jennings, Caroline M. Tanner, John Q. Trojanowski, Leslie M. Shaw, John Seibyl, Norbert Schuff, Andrew Singleton, Karl Kieburtz, Arthur W. Toga, Brit Mollenhauer, Doug Galasko, Lana M. Chahine, Daniel Weintraub, Tatiana Foroud, Duygu Tosun, Kathleen L. Poston, Vanessa Arnedo, Mark Frasier, Todd Sherer, the Parkinson's Progression Markers Initiative
How much of the research on Institute for Neurodegenerative Disorders is open access?
ScholarIQopen access share
92%OPEN ACCESS